Indications:
Non-Hodgkin’s lymphoma (NHL)
RUXIENCE is indicated for the treatment of:
• patients with CD20-positive diffuse large B-cell non-Hodgkin’s lymphoma (DLCL) in combination with cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) chemotherapy.
• previously untreated patients with stage III-IV follicular lymphoma in combination with cyclophosphamide, vincristine and prednisolone (CVP) chemotherapy.
patients with relapsed or chemoresistant indolent B-cell non-Hodgkin’s lymphomas.
RUXIENCE maintenance therapy is indicated for the treatment of follicular lymphoma patients responding to induction therapy.
Chronic lymphocytic leukaemia (CLL)
RUXIENCE is indicated in combination with fludarabine and cyclophosphamide (FC), for the treatment of patients with previously untreated and previously treated CD20-positive CLL.
Rheumatoid arthritis
RUXIENCE in combination with methotrexate is indicated for the treatment of adult patients with severe active rheumatoid arthritis who have had an inadequate response or intolerance to one or more tumour necrosis factor (TNF) inhibitor therapies.
|